Product Description
Ciforadenant (previously known as CPI-444) is a small molecule that potently and selectively binds A2AR, and competitively inhibits the binding and signaling of adenosine (25). Ciforadenant has been shown to be active in multiple preclinical tumor models both as a monotherapy and in combination with antiÐPD-1/PD-L1 (Sourced from: https://aacrjournals.org/cancerdiscovery/article/10/1/40/2261/Adenosine-2A-Receptor-Blockade-as-an-Immunotherapy)
Mechanisms of Action: ADORA2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Corvus
Company Location: BURLINGAME CA 94010
Company CEO: Richard A. Miller
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, France, Israel, South Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Expected - Corvus announced they will present P1 Kidney Cancer results in YE25 for Ciforadenant
- Clinical Outcomes Reported - Corvus announced they will present P2 Non-Small-Cell Lung Cancer results in 1H24 for Ciforadenant
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03337698 |
Morpheus Lung | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-11-30 |
12% |
2025-11-04 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |